Renofix 70 mg (Tablet)
Unit Price: ৳ 500.00 (1 x 12: ৳ 6,000.00)
Medicine Details
| Category | Details |
|---|---|
| Generic | Roxadustat |
| Company | Everest pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adult patients
Description
- First-in-class HIF-PH inhibitor
- Promotes erythropoiesis
- Increases endogenous production of erythropoietin
- Improves iron regulation
- Overcomes EPO-suppressive effects of inflammation on hemoglobin synthesis and red blood cell production
- Orally administered
Pharmacology
- Orally bioavailable
- HIF-PH inhibitor
- Promotes HIF activity
- Increases endogenous erythropoietin production
- Reduces hepcidin expression
- Improves iron availability
- Boosts hemoglobin (Hb) levels
- Regulates gene expression in response to reduced oxygen levels
- Induces coordinated erythropoiesis
- Maintains plasma erythropoietin levels within or near normal physiologic range
- Reduces dysregulation of iron metabolism associated with CKD
- Reduces cholesterol levels
- Binds to and inhibits HIF prolyl hydroxylase enzymes
- Promotes HIF transcriptional activity
- Increases haemoglobin (Hb) levels
- Reduces hepcidin levels
- Increases endogenous EPO levels
- Increases serum transferrin
- Increases intestinal iron absorption
- Reduces dysregulation of iron metabolism
- Reduces cholesterol levels
Dosage & Administration
- Orally administered
- Taken three times per week (not on consecutive days)
- Individualized dose to achieve and maintain target Hb levels of 10 to 12 g/dL
- Starting dose based on patient weight and erythropoiesis-stimulating agent treatment status
- Dose adjustment based on Hb monitoring
- Missed dose instructions
- Oral administration with or without food
Interaction
- Potential drug-drug interactions with phosphate binders, gemfibrozil, probenecid, OATP1B1, BCRP substrates
- Specific recommendations for dose adjustments and timing of administration
Side Effects
- Common adverse reactions include hypertension, vascular access thrombosis, diarrhea, peripheral edema, hyperkalemia, nausea
Pregnancy & Lactation
- Contraindicated during pregnancy and breastfeeding
Precautions & Warnings
- Use with caution in patients with pre-existing risk factors for thrombotic vascular events (TVE)
- Caution in patients with a history of seizures
- Contraindicated in patients with serious signs and symptoms of infection or liver disorder
- Not initiated in pregnant women
Use in Special Populations
- Not indicated for use in children
- Not recommended for use in patients with severe hepatic impairment
Overdose Effects
- Symptoms include increased heart rate and potentially excessive hemoglobin concentration
- Treatment involves appropriate dose reduction or interruption
- Not removed by dialysis
Therapeutic Class
- Drugs for Haemolytic Hypoplastic & Renal Anemia
Storage Conditions
- Store in a cool (below 30°C), dry place
- Away from light and moisture
- Keep out of the reach of children